The nomination processes for the 2021-2022 Slate of Officers and Board Members is now open.

The submission process
has closed.  

View the applicable pane below for more information. 

The responsibility of the 2020-2021 Nominating Committee is to develop the slate of leaders to stand for election to serve beginning in the 2021-2022 Society year:

• Second Vice President (The elected member will ascend to the President role and preside over the 2025 annual meeting.)
• Two members of the SPR Board of Directors
• Secretary-Elect (The elected member will serve from 2021-2022, and then assume the Secretary role from 2022-2025 for both the SPR and the SPR Research and Education Foundation.)
• One member of the SPR Research and Education Foundation Board

Review the expectations for Leaders here. Submit input via this online form.

Nominating Committee members are NOT eligible to be candidates for positions on the slate. 

The Nominating Committee roster can be viewed here.

The nomination process has passed.  Information for the 2021-2022 year will be posted winter 2021.

The information below remains visible for reference purposes only. 

Consider influencing the future of the Society by running for election to the 2020-2021 SPR Nominating Committee. Each year, the responsibility of the Committee is to develop the slate of officers to be voted on by the Members. To nominate an SPR member (including yourself) to serve on the Nominating Committee (the committee that identifies the next leaders of the Society), eligible members (Active, Allied, Emeritus, and Honorary) are asked to submit this online nomination form.

As mentioned, self-nomination is encouraged. Please keep the following in mind as you consider potential nominees:

• Candidates from the same institution as the continuing elected Nominating Committee members (not including the chair) are NOT eligible for positions on the slate. View the Nominating Committee. This criterion is being enforced in an effort to diversify the Nominating Committee and eliminate multiple recusals during its deliberations.

• The Anthem Guideline
• Talking points developed by the ACR
• A pertinent Aunt Minnie article 
• Template letter for your submission 

Periodically members of the Society as well as non-members seek to obtain the opinions, insight and expertise of the SPR membership.  If available, please review the survey(s) below and answer as you see fit.  Your participation is appreciated. 

The NCRP Recommendations for Ending Routine Gonadal Shielding During Abdominal and Pelvic Radiography is now accessible here. (Released January 13, 2021)

The NIH Common Fund received $30 Million from the Coronavirus Aid, Relief, and Economic Security (CARES) Act, 2020 to prevent, prepare for, and respond to coronavirus, domestically or internationally. The Office of Strategic Coordination (OSC), which manages the Common Fund, is using these funds to stimulate innovative, impactful research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and the disease it causes, Coronavirus Disease 2019 (COVID-19).

Today, OSC issued a Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (NOT-RM-20-015).

The NOSI describes the opportunity for emergency competitive revisions to Common Fund grants and cooperative agreements to support innovative, impactful research on COVID-19 or SARS-CoV-2 in any area of research including behavioral/social science, health disparities, and novel therapeutics that fits within the mission of an emergency response to provide critical expertise, resources or activities. OSC plans to use a portion of the CARES Act funds to support 10-20 high-impact, one-year, one-time, competitive revisions for Common Fund awards only in Fiscal year 2020. OSC is planning new funding opportunities to support new research projects in these areas beginning in Fiscal Year 2021.

Technical Assistance Webinar: OSC staff will host a technical assistance webinar to answer applicant questions on May 6, 2020. Additional details on the webinar will be added to this website: https://commonfund.nih.gov/covid19 as they become available. A recording of the webinar will not be posted online, but the slides and resultant Frequently Asked Questions (FAQs) will be posted here: NOSI FAQs page.

Application Due Dates: Applications will be accepted on a rolling basis from April 15, 2020 through June 19, 2020, by 5:00 PM local time of the applicant organization.

NIH Contacts for the NOSI: For questions concerning the NOSI for Fiscal Year 2020 competitive revisions to NIH Common Fund awards, please contact cfcovid19@od.nih.gov.  Please note that this mailbox is specific to funding opportunities from the NIH Common Fund.  For a list of COVID-19-related funding opportunities from multiple NIH Institutes, Centers, and Offices, please visit the COVID-19 page of information for NIH applicants and recipients of NIH funding.

  On April 29, 2020, the NIH launched the Rapid Acceleration of Diagnostics (RADx) Initiative.  For more information, access the following URL: https://directorsblog.nih.gov/2020/04/29/rising-to-the-covid-19-challenge-rapid-acceleration-of-diagnostics-radx/.

Regarding NIBIB and opportunities with the RADx initiative:

NIBIB expects to receive between 200-500 inquiries. translating to roughly 100 applications and, down the line, roughly five “outstanding, promising” approaches that the NIH could move to commercialize. The project is focused only on tests to diagnose Covid-19 in patients who are currently sick, not on serological tests that determine whether an individual carries antibodies that indicate they were previously infected with coronavirus.

The existing NIH-sponsored diagnostic development centers (POCTRN) will evaluate proposals and pair approved teams with experts in technology, regulatory approval, commercialization, and manufacturing to speed their progress. Proposals can use any technology to detect an active infection and will be evaluated for their likely success in improving testing performance—qualities such as speed, reliability, and accuracy—and ease of use, such as detecting the virus in saliva or exhaled breath.

This is a designated email to send inquiries which will be triaged and responded to quickly.  RADxNIBIB@mail.nih.gov

NIBIB has a webpage about RADx and other opportunities related to COVID-19: https://www.nibib.nih.gov/nibib-response-covid-19

Access the Statement Here 

• SBU. Shotgun - The role of the triad in the medical investigation of suspected chess violence. Stockholm: State Preparations for Medical and Social Evaluation (SBU); 2016. SBU Report No. 255. ISBN 978-91-85413-98-0.
  
• Google Translate Version